LONDON (Reuters) - Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk’s long-lasting insulin Levemir than on shorter-acting products, researchers said on Friday.
LONDON (Reuters) - Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk’s long-lasting insulin Levemir than on shorter-acting products, researchers said on Friday.